Full Press Release Details
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) --Septerna, Inc.(Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York.
A live webcast of the presentation will be availablehereand in the investors section of the company’s website atwww.septerna.com. The webcast will be archived for at least 30 days following the presentation.
About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visitwww.septerna.com.